CN108753677B - A kind of multifarious high-activity probiotics composition of improvement infant's intestinal flora - Google Patents
A kind of multifarious high-activity probiotics composition of improvement infant's intestinal flora Download PDFInfo
- Publication number
- CN108753677B CN108753677B CN201810719798.3A CN201810719798A CN108753677B CN 108753677 B CN108753677 B CN 108753677B CN 201810719798 A CN201810719798 A CN 201810719798A CN 108753677 B CN108753677 B CN 108753677B
- Authority
- CN
- China
- Prior art keywords
- freeze
- parts
- dried powder
- bifidobacterium
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000006041 probiotic Substances 0.000 title claims abstract description 132
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 132
- 239000000203 mixture Substances 0.000 title claims description 71
- 230000000968 intestinal effect Effects 0.000 title claims description 22
- 230000006872 improvement Effects 0.000 title claims description 13
- 230000000694 effects Effects 0.000 title description 21
- 230000000529 probiotic effect Effects 0.000 claims abstract description 67
- 235000013305 food Nutrition 0.000 claims abstract description 14
- 235000013373 food additive Nutrition 0.000 claims abstract description 4
- 239000002778 food additive Substances 0.000 claims abstract description 4
- 239000000843 powder Substances 0.000 claims description 160
- 241000186000 Bifidobacterium Species 0.000 claims description 54
- 241001465754 Metazoa Species 0.000 claims description 33
- 235000008476 powdered milk Nutrition 0.000 claims description 31
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims description 30
- 229940009289 bifidobacterium lactis Drugs 0.000 claims description 30
- 241000186840 Lactobacillus fermentum Species 0.000 claims description 29
- 241000254697 Lactobacillus rhamnosus HN001 Species 0.000 claims description 25
- 241000186012 Bifidobacterium breve Species 0.000 claims description 23
- 229920001353 Dextrin Polymers 0.000 claims description 16
- 239000004375 Dextrin Substances 0.000 claims description 16
- 235000019425 dextrin Nutrition 0.000 claims description 16
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 15
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 15
- 238000004108 freeze drying Methods 0.000 claims description 11
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims description 7
- 239000000273 veterinary drug Substances 0.000 claims description 3
- 241000193830 Bacillus <bacterium> Species 0.000 claims 1
- 235000020167 acidified milk Nutrition 0.000 claims 1
- 239000001963 growth medium Substances 0.000 abstract description 26
- 239000011148 porous material Substances 0.000 abstract description 18
- 239000002253 acid Substances 0.000 abstract description 10
- 238000000034 method Methods 0.000 abstract description 10
- 239000002609 medium Substances 0.000 abstract description 9
- 239000003814 drug Substances 0.000 abstract description 5
- 230000001737 promoting effect Effects 0.000 abstract description 5
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 abstract description 4
- 102000013275 Somatomedins Human genes 0.000 abstract description 4
- 238000009395 breeding Methods 0.000 abstract description 3
- 230000001488 breeding effect Effects 0.000 abstract description 3
- 230000007613 environmental effect Effects 0.000 abstract description 3
- 206010059866 Drug resistance Diseases 0.000 abstract description 2
- 210000003608 fece Anatomy 0.000 description 32
- 241000894006 Bacteria Species 0.000 description 31
- 239000000047 product Substances 0.000 description 31
- 238000000855 fermentation Methods 0.000 description 26
- 230000004151 fermentation Effects 0.000 description 26
- 239000007788 liquid Substances 0.000 description 26
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 24
- 238000012360 testing method Methods 0.000 description 22
- 241000186660 Lactobacillus Species 0.000 description 18
- 229940039696 lactobacillus Drugs 0.000 description 18
- 150000001875 compounds Chemical class 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 14
- 239000007787 solid Substances 0.000 description 14
- 241001591005 Siga Species 0.000 description 13
- 235000013361 beverage Nutrition 0.000 description 13
- 230000000052 comparative effect Effects 0.000 description 13
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 12
- 108010035532 Collagen Proteins 0.000 description 11
- 102000008186 Collagen Human genes 0.000 description 11
- 229920001436 collagen Polymers 0.000 description 11
- 238000001514 detection method Methods 0.000 description 11
- 239000005862 Whey Substances 0.000 description 10
- 102000007544 Whey Proteins Human genes 0.000 description 10
- 108010046377 Whey Proteins Proteins 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 239000011812 mixed powder Substances 0.000 description 10
- 235000021391 short chain fatty acids Nutrition 0.000 description 10
- 150000004666 short chain fatty acids Chemical class 0.000 description 10
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 9
- 229930006000 Sucrose Natural products 0.000 description 9
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 9
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 9
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 9
- 239000005720 sucrose Substances 0.000 description 9
- 230000001580 bacterial effect Effects 0.000 description 8
- 230000036541 health Effects 0.000 description 8
- 238000002156 mixing Methods 0.000 description 8
- 230000009286 beneficial effect Effects 0.000 description 7
- 150000004676 glycans Chemical class 0.000 description 7
- 235000020256 human milk Nutrition 0.000 description 7
- 210000004251 human milk Anatomy 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 229920001282 polysaccharide Polymers 0.000 description 6
- 239000005017 polysaccharide Substances 0.000 description 6
- 235000019260 propionic acid Nutrition 0.000 description 6
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 230000008901 benefit Effects 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 210000000481 breast Anatomy 0.000 description 4
- 238000010835 comparative analysis Methods 0.000 description 4
- 230000002550 fecal effect Effects 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 230000008944 intestinal immunity Effects 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 238000012856 packing Methods 0.000 description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 239000007640 basal medium Substances 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 238000004945 emulsification Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 239000002054 inoculum Substances 0.000 description 3
- 235000013406 prebiotics Nutrition 0.000 description 3
- 239000003223 protective agent Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- 235000013618 yogurt Nutrition 0.000 description 3
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 108010022355 Fibroins Proteins 0.000 description 2
- 108010068370 Glutens Proteins 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000004964 aerogel Substances 0.000 description 2
- 239000006229 carbon black Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000002657 fibrous material Substances 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 229920001519 homopolymer Polymers 0.000 description 2
- 229910010272 inorganic material Inorganic materials 0.000 description 2
- 239000011147 inorganic material Substances 0.000 description 2
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000013335 mesoporous material Substances 0.000 description 2
- 244000005706 microflora Species 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 210000004994 reproductive system Anatomy 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- PUKLDDOGISCFCP-JSQCKWNTSA-N 21-Deoxycortisone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2=O PUKLDDOGISCFCP-JSQCKWNTSA-N 0.000 description 1
- REKYPYSUBKSCAT-UHFFFAOYSA-N 3-hydroxypentanoic acid Chemical compound CCC(O)CC(O)=O REKYPYSUBKSCAT-UHFFFAOYSA-N 0.000 description 1
- QJZYHAIUNVAGQP-UHFFFAOYSA-N 3-nitrobicyclo[2.2.1]hept-5-ene-2,3-dicarboxylic acid Chemical compound C1C2C=CC1C(C(=O)O)C2(C(O)=O)[N+]([O-])=O QJZYHAIUNVAGQP-UHFFFAOYSA-N 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 244000061520 Angelica archangelica Species 0.000 description 1
- 241000239290 Araneae Species 0.000 description 1
- 240000002900 Arthrospira platensis Species 0.000 description 1
- 235000016425 Arthrospira platensis Nutrition 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 241000190633 Cordyceps Species 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 241000026010 Dendrobium candidum Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000520130 Enterococcus durans Species 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- FCYKAQOGGFGCMD-UHFFFAOYSA-N Fulvic acid Natural products O1C2=CC(O)=C(O)C(C(O)=O)=C2C(=O)C2=C1CC(C)(O)OC2 FCYKAQOGGFGCMD-UHFFFAOYSA-N 0.000 description 1
- 240000008397 Ganoderma lucidum Species 0.000 description 1
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 235000001287 Guettarda speciosa Nutrition 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- 229920002752 Konjac Polymers 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 201000010538 Lactose Intolerance Diseases 0.000 description 1
- 229920001491 Lentinan Polymers 0.000 description 1
- 229920002097 Lichenin Polymers 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
- 229920001397 Poly-beta-hydroxybutyrate Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920000331 Polyhydroxybutyrate Polymers 0.000 description 1
- 238000012356 Product development Methods 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241001506047 Tremella Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 229920002494 Zein Polymers 0.000 description 1
- 108010055615 Zein Proteins 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940107666 astragalus root Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 235000008452 baby food Nutrition 0.000 description 1
- 241000698924 bacterium SR 19 Species 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 229940077731 carbohydrate nutrients Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 235000015190 carrot juice Nutrition 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- SHFGJEQAOUMGJM-UHFFFAOYSA-N dialuminum dipotassium disodium dioxosilane iron(3+) oxocalcium oxomagnesium oxygen(2-) Chemical compound [O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[Na+].[Na+].[Al+3].[Al+3].[K+].[K+].[Fe+3].[Fe+3].O=[Mg].O=[Ca].O=[Si]=O SHFGJEQAOUMGJM-UHFFFAOYSA-N 0.000 description 1
- GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 229960002737 fructose Drugs 0.000 description 1
- 229940095100 fulvic acid Drugs 0.000 description 1
- 239000002509 fulvic acid Substances 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 239000004021 humic acid Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940115286 lentinan Drugs 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229910052901 montmorillonite Inorganic materials 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 235000019707 mung bean protein Nutrition 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- 235000019362 perlite Nutrition 0.000 description 1
- 239000010451 perlite Substances 0.000 description 1
- 229940068041 phytic acid Drugs 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 239000000467 phytic acid Substances 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 239000004632 polycaprolactone Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- -1 poromerics Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 125000003748 selenium group Chemical class *[Se]* 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000011497 sour milk drink Nutrition 0.000 description 1
- 235000019710 soybean protein Nutrition 0.000 description 1
- 229940082787 spirulina Drugs 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 235000015193 tomato juice Nutrition 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000005019 zein Substances 0.000 description 1
- 229940093612 zein Drugs 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/38—Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
- A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/163—Sugars; Polysaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/143—Fermentum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/175—Rhamnosus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/515—Animalis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/519—Breve
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/531—Lactis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Zoology (AREA)
- Polymers & Plastics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Food Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Animal Husbandry (AREA)
- General Chemical & Material Sciences (AREA)
- Physiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a kind of cultural methods of probiotics, porous material is added in the culture medium containing the somatomedin for promoting growth of probiotics breeding, the volume ratio of culture medium and porous material is 1: 100, is inoculated with probiotics in the medium and is cultivated, realizes probiotic's culture；Probiotics obtained can be used for preparing the products such as food, food additives, medicine, feed or environmental protection treatment.The probiotics that the present invention obtains has the performances such as good heat resistance, acid resistance and drug resistance, has broad application prospects in fields such as food, medicine, feed, environmental protection.
Description
Technical field
The invention belongs to probiotic composition fields, and in particular to a kind of improvement infant's intestinal flora is multifarious high living
Property probiotic composition
Background technique
Probiotics is a kind of active microorganism beneficial to host, is to be colonized in human body intestinal canal, in reproductive system, can generate
Definite health efficacy so as to improve host's microecological balance, play the active beneficial microorganism general name of beneficial effect.Supplement benefit
Raw bacterium not only can coordinating intestines and stomach, moreover it is possible to enhance human immunity, alleviate lactose intolerance lactose disease, prevention genital system infection, promote
Into enteron aisle digestive system health, serum cholesterol is reduced, help absorbs nutritional ingredient, brings up healthy enteron aisle.Research in recent years
Show that bacterium is the abundantest in the intracorporal bacterium of people up to more than 1000 kinds, especially gastrointestinal tract, Zhan Quanshen micro-ecological bacterial sum
80% or so, it is 10 times of human body cell, is known as " the second genome " of the mankind.These be found to be probiotic products food,
The application in the fields such as health care product, medicine, cultivation, environment, amenities brings huge motive force.Currently, probiotics is wide
It is general in the products such as Yoghourt, sour milk beverage, probiotics powder agent, animal feed, environmental improvement, form relative to it is complete and at
Ripe probiotics industry.Need special it is noted that probiotics could be in place when probiotics only reaches certain quantity levels
Corresponding effect is generated in main body.So needing to guarantee using probiotics as the food of functional component, health care product or drug contained living
Probiotics quantity be maintained at certain level.This demand proposes corresponding requirement to the production and preparation of probiotics, existing
Have in technology, the method for probiotics activation culture is more traditional, and obtained seed liquor activity is not high, causes application effect poor.
With people's living standard as the improvement of people's living standards, to health requirement it is also higher and higher, it is prebiotic
Bacterium is universal to be received and is widely used.The concept of probiotics was suggested in 1989, and scientist determines probiotics within 2002
Concept and curative effect.Short ten years later world human health field has occurred huge variation, the research of probiotics prebiotics and
Product development becomes trend.Research and development, the production in the field, it is outstanding in lactic acid bacteria, the research of Bifidobacterium and application aspect at present
It is protruded.The product of this respect has traditional Yoghourt and various Yoghourts newly developed, lactic acid drink, and various list compound bacterias are protected
Strong product, food, there are also the probiotics preparations for treating intestines problem.Because the preservation condition of probiotics is harsh, existing product
The technical issues of easily dead in the prevalence of viable bacteria, bacterium number is unstable, causes the probiotic products shelf-life short, unstable quality.
For example, disclosed in Chinese patent application 201710288326.2 a kind of probiotics homobium, cultural method and its
Using it discloses the goldbeater's skins for having cultivated Enterococcus durans CR-29 and the CGMCC number 11869 including CGMCC number 11870
Leukonid goldbeater's skin subspecies bacterium SR-19, obtains homobium probiotics bacterial powder, is used for food, food additives, health food, people
The raw field of class drug, veterinary drug, animal feed.But the application, which is applied to the effect in food etc. for probiotics, not to retouch
It states.
Because probiotics can bring a variety of benefits to human body, people start to consider to be applied to infant food
In, but infant's keratoderma, than relatively thin, capillary network is abundant and endothelium is aqueous and chloride is relatively more, to various
Stimulus is more sensitive, and baby digests and assimilates poor in addition, and gastrointestinal tract defence capability is weaker, and food cannot sufficiently digest decomposition,
And blood is absorbed into the form of macromolecular, and although the probiotics drink used in exploitation for infant at present, type
Seldom.
For example, disclosing a kind of probiotic composition and its application, baby children in Chinese patent application 201310742689.0
Youngster's food, the probiotic composition include Bifidobacterium HN019 and Lactobacillus rhamnosus HN001.Infant provided by the invention
Food can significantly improve Bifidobacterium and lactobacillus content in baby intestinal, while significantly reduce Bacillus perfringens content,
To be effectively improved the micro-ecological environment of baby intestinal；The acetic acid content and short chain fatty acids in infant faeces can be significantly improved
Total content, and close to Pure breast feeding baby；The sIgA content in infant faeces can be significantly improved, and is fed close to pure breast milk
Support baby；The eczema occurrence rate of baby can be significantly reduced.But added probiotics type is less in the invention, to changing
Kind infant's intestinal flora diversity effect is not particularly evident.
Based on the deficiencies in the prior art, a kind of cultural method of compound probiotic is provided, and by the compound of culture
For probiotics for improving infant's intestinal flora diversity, which is of great significance for the large-scale application of probiotics.
Summary of the invention
In order to solve the above-mentioned technical problem, the present invention is intended to provide a kind of cultural method of probiotics and its application, are used for
On the one hand the technical issues of solving the problems, such as is that probiotics is difficult to last preservation in existing probiotic beverage, be on the other hand to expand
Application of the probiotics in terms of improving infant's intestinal flora diversity.
On the one hand, the present invention provides a kind of cultural methods of probiotics
Porous material is added in the culture medium containing the somatomedin for promoting growth of probiotics breeding, culture medium and more
The volume ratio of Porous materials is 1:100, is inoculated with probiotics in the medium and is cultivated, realizes probiotics High Density Cultivation.
The culture is Anaerobic culturel, and the probiotics being inoculated with is the microorganism of anaerobism or amphimicrobian.
Anaerobic culturel is to cultivate 12-48h at 30-42 DEG C.
After culture, the probiotics gathers the surface of porous material or inside or surface and inside are done
Total viable count is up to 10 in product after dry11-1015CFU/g or more.Mean living is influenced by factors such as drying means, and freezing is dry
Viable count is higher in dry product.
Preparation-obtained probiotics has the performances such as good heat resistance, acid resistance, that is, drug resistance.
The culture medium is liquid, semisolid or solid-state, and cultivating system can be Liquid Culture, Semi-solid cell culture and consolidate
Any one of training method in body culture three, the porous material are solid.
The culture medium is Medium of Bifidobacterium (bifidobacterium lactis, animal bifidobacteria, bifidobacterium breve)；
SIIM0012 culture medium (Lactobacillus rhamnosus, lactobacillus fermenti) etc..
Contain the somatomedin for promoting growth of probiotics breeding in the culture medium.It is numerous containing promotion growth of probiotics
The somatomedin grown such as whey fermentation liquid, collagen fermentation liquid, potato fermentation liquid, marine algae extract, mushroom fermentation
Liquid or extract, soya-bean milk, tomato juice, carrot juice, corn juice, Cordyceps extract, Ganodenna Lucidum P.E, dendrobium candidum go to mention
Take object, angelica extract, ginkgo biloba p.e, malt extract, ginseng class extract, Astragalus Root P.E, Fructus Monordicae extract, chrysanthemum
Powder, yeast dextran, xylo-oligosaccharide, vitamin, amino acid, dopamine, phytic acid, fulvic acid, humic acid, magnesium salts, zinc salt, manganese
The one or more of salt, calcium salt, molysite, selenium salt etc..
The mean pore size of porous material in the culture medium is 1 nanometer -500 microns, volumetric porosity 5-
99.9%(v/v).The volume ratio for 5-99.9%(v/v) referring to that the hole of porous material accounts for entire material is 5-99.9%.
The porous material is gel rubber material, aerogel material, foamed material, fibrous material, poromerics, mesoporous material
Material or large pore material etc..
The gel rubber material, aerogel material, foamed material and fibrous material average pore size from nano-grade size to
Micron order size differs；The average pore size of the poromerics less than 2 nanometers, receive for 2-50 by the average pore size of mesoporous material
The average pore size of rice, large pore material is greater than 50 nanometers.
The porous material is natural polysaecharides and its derivative, native protein class and its derivative, synthesis macromolecule
Homopolymer or one or more of materials such as copolymer, inorganic material.
Natural polysaecharides such as chitin, chitosan, vitamin, lignin, cellulose, glucan, agarose, oligomeric fruit
Sugar, soyabean oligosaccharides, the sweet glycan of konjaku Pu, oligoisomaltose, xylo-oligosaccharide, oligomeric maltose, starch, dextrin, inulin, sea
Alginic acid and its salt, dextran, hyaluronic acid, algal polysaccharides, algal polysaccharide, spirulina polysaccharide, lichenin, lentinan,
The sources such as ganoderma lucidum polysaccharide, tremella polysaccharides, Arabic gum, pectin, guar gum, xanthan gum carrageenan and plant, animal, seaweed breathe out
More carbohydrates and their derivatives of microorganism.
Native protein class such as soybean protein, mung bean protein, wheat gluten, zein, glutelin, fibroin, spider
The sources such as silk-fibroin, collagen, lactalbumin, gelatin, casein sodium, fibrin, keratin and plant, animal and micro-
The albumen and its derivative of biology.
Synthesize the poly- hydroxyl second of high molecular homopolymer and copolymer such as polyaminoacid, polyethylene glycol, polylactic acid, polylactic acid-
Acid copolymer, polyvinylpyrrolidone, polycaprolactone, poly beta-hydroxybutyrate, poly- β hydroxypentanoic acid etc..
Inorganic material such as perlite, montmorillonite, carbon black, white carbon black, ceramics etc..
Probiotics used is the microorganism to human body and (or) animal health.As bifidobacterium lactis, animal bifidobacteria,
One or more of bifidobacterium breve, Lactobacillus rhamnosus, lactobacillus fermenti etc..
In the culture medium, the probiotics bacterial liquid measure being inoculated on porous material is 0.1%-50% (v/v).0.1%-50%(v/
V) refer to that the volume that probiotics bacterial liquid is added is that entirely the volume of culture medium is 0.1-50% after being added.
The concentration of bacterium solution in affiliated probiotics inoculation bacterium solution is 108-109CFU/mL。
The invention belongs to probiotic composition fields, and in particular to a kind of improvement infant's intestinal flora is multifarious high living
Property probiotic composition.
The present invention provides a kind of multifarious high-activity probiotics composition of improvement infant's intestinal flora, the benefits
Raw bacteria composition, includes following components according to parts by weight:
40-60 parts of resistant dextrin, 5-15 parts of galactooligosaccharide, 5-15 parts of oligofructose, bifidobacterium lactis HN019 freeze-dried powder
2-8 parts, 2-8 parts of animal bifidobacteria BB-12 freeze-dried powder, 2-8 parts of bifidobacterium breve M-16V freeze-dried powder, Lactobacillus rhamnosus
2-8 parts and 2-8 parts of lactobacillus fermenti CECT5716 freeze-dried powder of HN001 freeze-dried powder.
Preferably, above-mentioned probiotic composition includes following components according to parts by weight:
50-60 parts of resistant dextrin, 8-12 parts of galactooligosaccharide, 8-12 parts of oligofructose, bifidobacterium lactis HN019 freeze-dried powder
3-7 parts, 3-7 parts of animal bifidobacteria BB-12 freeze-dried powder, 3-7 parts of bifidobacterium breve M-16V freeze-dried powder, Lactobacillus rhamnosus
3-7 parts and 3-7 parts of lactobacillus fermenti CECT5716 freeze-dried powder of HN001 freeze-dried powder.
It is further preferred that above-mentioned probiotic composition, includes following components according to parts by weight:
40-50 parts of resistant dextrin, 9-11 parts of galactooligosaccharide, 9-11 parts of oligofructose, bifidobacterium lactis HN019 freeze-dried powder
4-6 parts, 4-6 parts of animal bifidobacteria BB-12 freeze-dried powder, 4-6 parts of bifidobacterium breve M-16V freeze-dried powder, Lactobacillus rhamnosus
4-6 parts and 4-6 parts of lactobacillus fermenti CECT5716 freeze-dried powder of HN001 freeze-dried powder.
Above-mentioned probiotic composition, the bifidobacterium lactis HN019 freeze-dried powder, animal bifidobacteria BB-12 freeze-dried powder
M1, described ground Lactobacillus rhamnosus HN001 freeze-dried powder and fermentation are calculated as with the total weight number of bifidobacterium breve M-16V freeze-dried powder
The total weight number of lactobacillus CECT5716 freeze-dried powder is calculated as M2, and the ratio between M1 and M2 are 2-5:2；Preferably 3-4:2.
Bifidobacterium lactis HN019 freeze-dried powder, animal bifidobacteria BB-12 freeze-dried powder and the bifidobacterium breve M-16V
The ratio between parts by weight of freeze-dried powder are 0.5-3:1:1；Preferably, the bifidobacterium lactis HN019 freeze-dried powder, animal bifid bar
The ratio between parts by weight of bacterium BB-12 freeze-dried powder and bifidobacterium breve M-16V freeze-dried powder are 1-2.5:1:1；More preferably, described
The parts by weight of bifidobacterium lactis HN019 freeze-dried powder, animal bifidobacteria BB-12 freeze-dried powder and bifidobacterium breve M-16V freeze-dried powder
The ratio between number is 1.5-2:1:1.
The ratio between the parts by weight of the Lactobacillus rhamnosus HN001 freeze-dried powder and lactobacillus fermenti CECT5716 freeze-dried powder
For 1:0.5-4；Preferably, the weight of the Lactobacillus rhamnosus HN00 freeze-dried powder 1 and lactobacillus fermenti CECT5716 freeze-dried powder
Measuring the ratio between number is 1:1-3.5；More preferably, the Lactobacillus rhamnosus HN001 freeze-dried powder and lactobacillus fermenti
The ratio between parts by weight of CECT5716 freeze-dried powder are 1:1.5-3；It is further preferred that the Lactobacillus rhamnosus HN001 freezes
The ratio between parts by weight of dry powder and lactobacillus fermenti CECT5716 freeze-dried powder are 1:2-2.5.
The bifidobacterium lactis HN019 freeze-dried powder, animal bifidobacteria BB-12 freeze-dried powder, bifidobacterium breve M-16V freeze
The viable count of dry powder, Lactobacillus rhamnosus HN001 freeze-dried powder and lactobacillus fermenti CECT5716 freeze-dried powder is 107-1010CFU/
G, and moisture content is lower than 4%.
Above-mentioned probiotic composition can be applied to food, food additives, health food, human food, veterinary drug, animal feeding
Material aspect.
Above-mentioned probiotic composition is applied to probiotics solid beverage in a preferred embodiment.
In a specific embodiment, the probiotics solid beverage includes following components according to parts by weight:
40 parts of resistant dextrin, 8 parts of galactooligosaccharide, 10 parts of oligofructose, 8 parts of bifidobacterium lactis HN019 freeze-dried powder, animal
4 parts of Bifidobacterium BB-12 freeze-dried powder, 4 parts of bifidobacterium breve M-16V freeze-dried powder, 2 parts of Lactobacillus rhamnosus HN001 freeze-dried powder and
6 parts of lactobacillus fermenti CECT5716 freeze-dried powder.
In another embodiment, the probiotics solid beverage includes following components according to parts by weight:
60 parts of resistant dextrin, 15 parts of galactooligosaccharide, 8 parts of oligofructose, 3 parts of bifidobacterium lactis HN019 freeze-dried powder, animal
6 parts of Bifidobacterium BB-12 freeze-dried powder, 6 parts of bifidobacterium breve M-16V freeze-dried powder, 6 parts of Lactobacillus rhamnosus HN001 freeze-dried powder and
4 parts of lactobacillus fermenti CECT5716 freeze-dried powder.
The present invention also provides a kind of method for preparing above-mentioned probiotics solid beverage, specific steps include:
(1) it prepares powder: resistant dextrin, galactooligosaccharide and oligofructose being crossed into 50-120 mesh respectively, then by 3 kinds
Powder is stirred evenly repeatedly by the mixing of formulation weight number, obtains mixed-powder A, spare；
(2) compound probiotic composition is prepared: by bifidobacterium lactis HN019, animal bifidobacteria BB-12, short bifid bar
Bacterium M-16V, Lactobacillus rhamnosus HN001 and lactobacillus fermenti CECT5716 are respectively put into test tube and activate, and obtain first order seed
Liquid；Then primary seed solution is inoculated in condition of culture in culture medium A is 25~42 DEG C, Anaerobic culturel 8~obtain second level kind for 24 hours
Sub- liquid；Secondary seed solution is respectively connected to carry out high density fermentation in fermentation medium, inoculum concentration 0.5%-5%, cultivates item
Part is 30~40 DEG C, and 8~18h of Anaerobic culturel collects fermentation liquid respectively；
(3) fermentation liquid described in step (2) is centrifuged respectively, protective agent emulsification is added after collecting thallus, vacuum is cold respectively
Dry obtained bacterium powder is lyophilized, bacterium powder is then mixed to get mixing probiotic powder B by the parts by weight in formula.
(3) it is mixed: mixed-powder A obtained in step (1) is added in blender, suitable water starting is added
Blender is added mixing probiotic powder B by given pace during being stirred for, stirs evenly, obtain until mixed-powder A dissolves
To mixture C；
(4) it is freeze-dried: mixture C obtained in step (4) being placed in refrigerator and is freeze-dried, is frozen
Dry powder D；
(5) crushing packing: freeze-dried powder D obtained in step (4) being placed in pulverizer and is crushed, and then crosses 200-
600 meshes obtain compound probiotic freeze-drying powder solid beverage, and compound probiotic freeze-drying powder solid beverage is then put into packing machine
It is medium packaged to get finished product.
Culture medium A described in above-mentioned steps (2) is that a certain amount of collagen egg is added in basal medium MRS culture medium
White, trehalose, sucrose, whey fermentation liquid and vitamin C, stir evenly, and sterilize 20-30min, that is, culture medium A is prepared；Its
Mass percent shared by middle MRS culture medium is 70%, mass percent shared by collagen, trehalose, sucrose and whey fermentation liquid
It is 30%；Collagen, trehalose, sucrose and whey fermentation liquid mass ratio be 1:1:3:5.
The amount of addition suitable quantity of water described in above-mentioned steps (3) is just to be completely dissolved mixed-powder A；Described is compound
The addition speed of probiotics is 0.5 part/minute.
Freeze-drying time described in above-mentioned steps (4) is 18-36h.
Grinding time described in above-mentioned steps (5) is 30-90min.
Beneficial effects of the present invention:
(1) compound probiotic composition disclosed by the invention makes each bacterial strain by adjusting the type and content of probiotics
Between can interact, can preferably promote absorption of infant's stomach and intestine to nutriment.
(2) the invention discloses a kind of probiotic bacteria culture mediums, make the probiotics activity with higher of culture, can pass through
The increase for promoting enteron aisle Short-Chain Fatty Acids improves the content of organic acid, reduces gut pH, and enteron aisle acidity is caused to reduce and press down
Harmful bacteria processed increases beneficial to bacterial content.
(3) the invention discloses a kind of high-activity probiotics composition, the composition can improve infant's intestinal flora
Diversity can play promotion digestion, the effects of stimulating intestine immunity cell, enhance infant's intestinal immunity.
Specific embodiment
Bifidobacterium lactis HN019 freeze-dried powder, Lactobacillus rhamnosus HN001 freeze-dried powder used in following embodiment move
Object Bifidobacterium BB-12 freeze-dried powder, bifidobacterium breve M-16V freeze-dried powder and lactobacillus fermenti CECT5716 freeze-dried powder are purchased from beauty
The companies such as biology are applied in Du Pont, state, section, Denmark Hansen and Shanghai hundred.
A kind of multifarious high-activity probiotics composition of improvement infant's intestinal flora of embodiment 1
Formula: including following components according to parts by weight:
40 parts of resistant dextrin, 8 parts of galactooligosaccharide, 10 parts of oligofructose, 8 parts of bifidobacterium lactis HN019 freeze-dried powder, animal
4 parts of Bifidobacterium BB-12 freeze-dried powder, 4 parts of bifidobacterium breve M-16V freeze-dried powder, 2 parts of Lactobacillus rhamnosus HN001 freeze-dried powder and
6 parts of lactobacillus fermenti CECT5716 freeze-dried powder.
Preparation method: specific steps include:
(1) it prepares powder: resistant dextrin, galactooligosaccharide and oligofructose is sieved with 100 mesh sieve respectively, then by 3 kinds of powder
End is stirred evenly repeatedly by the mixing of formulation weight number, obtains mixed-powder A, spare；
(2) compound probiotic composition is prepared: by bifidobacterium lactis HN019, animal bifidobacteria BB-12, short bifid bar
Bacterium M-16V, Lactobacillus rhamnosus HN001 and lactobacillus fermenti CECT5716 are respectively put into test tube and activate, and obtain first order seed
Liquid；Then primary seed solution is inoculated in condition of culture in culture medium A is 30 DEG C, and Anaerobic culturel 20h obtains secondary seed solution；It will
Secondary seed solution is respectively connected to carry out high density fermentation in fermentation medium, inoculum concentration 4%, and condition of culture is 35 DEG C, anaerobism
12h is cultivated, collects fermentation liquid respectively；
(3) fermentation liquid described in step (2) is centrifuged respectively, protective agent emulsification is added after collecting thallus, vacuum is cold respectively
Dry obtained bacterium powder is lyophilized, bacterium powder is then mixed to get mixing probiotic powder B by the parts by weight in formula.
(3) it is mixed: mixed-powder A obtained in step (1) is added in blender, suitable water starting is added
Mixing probiotic powder B, stirring is added by the speed of 0.5 part/minute during being stirred for until mixed-powder A dissolves in blender
Uniformly, mixture C is obtained；
(4) it is freeze-dried: mixture C obtained in step (4) being placed in refrigerator and carries out freeze-drying 18h, is obtained
To freeze-dried powder D；
(5) crushing packing: freeze-dried powder D obtained in step (4) is placed in pulverizer and carries out crushing 40min, then
600 meshes are crossed, compound probiotic freeze-drying powder solid beverage is obtained, compound probiotic freeze-drying powder solid beverage is then put into packaging
Machine is medium packaged to get finished product.
Culture medium A described in above-mentioned steps (2) is that a certain amount of collagen egg is added in basal medium MRS culture medium
White, trehalose, sucrose, whey fermentation liquid and vitamin C, stir evenly, and sterilize 20-30min, that is, culture medium A is prepared；Its
Mass percent shared by middle MRS culture medium is 70%, mass percent shared by collagen, trehalose, sucrose and whey fermentation liquid
It is 30%；Collagen, trehalose, sucrose and whey fermentation liquid mass ratio be 1:1:3:5.
A kind of multifarious high-activity probiotics composition of improvement infant's intestinal flora of embodiment 2
Formula: including following components according to parts by weight:
60 parts of resistant dextrin, 15 parts of galactooligosaccharide, 8 parts of oligofructose, 3 parts of bifidobacterium lactis HN019 freeze-dried powder, animal
6 parts of Bifidobacterium BB-12 freeze-dried powder, 6 parts of bifidobacterium breve M-16V freeze-dried powder, 6 parts of Lactobacillus rhamnosus HN001 freeze-dried powder and
4 parts of lactobacillus fermenti CECT5716 freeze-dried powder.
Preparation method: specific steps include: other operations and step and 1 phase of embodiment in addition to each component content is different
Together.
A kind of multifarious high-activity probiotics composition of improvement infant's intestinal flora of embodiment 3
Formula: including following components according to parts by weight:
50 parts of resistant dextrin, 12 parts of oligofructose, 8 parts of bifidobacterium lactis HN019 freeze-dried powder, moves 12 parts of galactooligosaccharide
4 parts of object Bifidobacterium BB-12 freeze-dried powder, 4 parts of bifidobacterium breve M-16V freeze-dried powder, 2 parts of Lactobacillus rhamnosus HN001 freeze-dried powder
With 8 parts of lactobacillus fermenti CECT5716 freeze-dried powder.
Preparation method: specific steps include: other operations and step and 1 phase of embodiment in addition to each component content is different
Together.
A kind of multifarious high-activity probiotics composition of improvement infant's intestinal flora of embodiment 4
Formula: including following components according to parts by weight:
45 parts of resistant dextrin, 13 parts of oligofructose, 2 parts of bifidobacterium lactis HN019 freeze-dried powder, moves 10 parts of galactooligosaccharide
4 parts of object Bifidobacterium BB-12 freeze-dried powder, 4 parts of bifidobacterium breve M-16V freeze-dried powder, 5 parts of Lactobacillus rhamnosus HN001 freeze-dried powder
With 5 parts of lactobacillus fermenti CECT5716 freeze-dried powder.
Preparation method: specific steps include: that (1) prepares powder: resistant dextrin, galactooligosaccharide and oligofructose are distinguished
120 meshes are crossed, 3 kinds of powder are mixed by formulation weight number then and are stirred evenly repeatedly, mixed-powder A is obtained, it is spare；
(2) compound probiotic composition is prepared: by bifidobacterium lactis HN019, animal bifidobacteria BB-12, short bifid bar
Bacterium M-16V, Lactobacillus rhamnosus HN001 and lactobacillus fermenti CECT5716 are respectively put into test tube and activate, and obtain first order seed
Liquid；Then primary seed solution is inoculated in condition of culture in culture medium A is 35 DEG C, and Anaerobic culturel 18h obtains secondary seed solution；It will
Secondary seed solution is respectively connected to carry out high density fermentation in fermentation medium, inoculum concentration 3%, and condition of culture is 30 DEG C, anaerobism
18h is cultivated, collects fermentation liquid respectively；
(3) fermentation liquid described in step (2) is centrifuged respectively, protective agent emulsification is added after collecting thallus, vacuum is cold respectively
Dry obtained bacterium powder is lyophilized, bacterium powder is then mixed to get mixing probiotic powder B by the parts by weight in formula.
(3) it is mixed: mixed-powder A obtained in step (1) is added in blender, suitable water starting is added
Mixing probiotic powder B, stirring is added by the speed of 0.5 part/minute during being stirred for until mixed-powder A dissolves in blender
Uniformly, mixture C is obtained；
(4) it is freeze-dried: mixture C obtained in step (4) being placed in refrigerator and is freeze-dried for 24 hours, is obtained
To freeze-dried powder D；
(5) crushing packing: freeze-dried powder D obtained in step (4) is placed in pulverizer and carries out crushing 30min, then
400 meshes are crossed, compound probiotic freeze-drying powder solid beverage is obtained, compound probiotic freeze-drying powder solid beverage is then put into packaging
Machine is medium packaged to get finished product.
Culture medium A described in above-mentioned steps (2) is that a certain amount of collagen egg is added in basal medium MRS culture medium
White, trehalose, sucrose, whey fermentation liquid and vitamin C, stir evenly, and sterilize 20-30min, that is, culture medium A is prepared；Its
Mass percent shared by middle MRS culture medium is 70%, mass percent shared by collagen, trehalose, sucrose and whey fermentation liquid
It is 30%；Collagen, trehalose, sucrose and whey fermentation liquid mass ratio be 1:1:3:5.
A kind of multifarious high-activity probiotics composition of improvement infant's intestinal flora of embodiment 5
Formula: including following components according to parts by weight:
55 parts of resistant dextrin, 10 parts of oligofructose, 7 parts of bifidobacterium lactis HN019 freeze-dried powder, moves 13 parts of galactooligosaccharide
5 parts of object Bifidobacterium BB-12 freeze-dried powder, 5 parts of bifidobacterium breve M-16V freeze-dried powder, 6 parts of Lactobacillus rhamnosus HN001 freeze-dried powder
With 3 parts of lactobacillus fermenti CECT5716 freeze-dried powder.
Preparation method: specific steps include: other operations and step and 4 phase of embodiment in addition to each component content is different
Together.
A kind of probiotic composition of comparative example 1
The difference from embodiment 1 is that: bifidobacterium lactis HN019 freeze-dried powder, animal bifidobacteria BB-12 freeze-dried powder and short
The total weight number and Lactobacillus rhamnosus HN001 freeze-dried powder and lactobacillus fermenti CECT5716 of Bifidobacterium M-16V freeze-dried powder
The ratio between total weight number of freeze-dried powder is 1:2.
Preparation method: specific steps include: other operations and step and 1 phase of embodiment in addition to each component content is different
Together.
A kind of probiotic composition of comparative example 2
The difference from embodiment 1 is that: bifidobacterium lactis HN019 freeze-dried powder, animal bifidobacteria BB-12 freeze-dried powder and short
The total weight number and Lactobacillus rhamnosus HN001 freeze-dried powder and lactobacillus fermenti CECT5716 of Bifidobacterium M-16V freeze-dried powder
The ratio between total weight number of freeze-dried powder is 3:1.
Preparation method: specific steps include: other operations and step and 1 phase of embodiment in addition to each component content is different
Together.
A kind of probiotic composition of comparative example 3
The difference from example 2 is that: Lactobacillus rhamnosus HN001 freeze-dried powder and lactobacillus fermenti CECT5716 freeze-dried powder
The ratio between parts by weight be 1:0.1.
Preparation method: specific steps include: other operations and step and 2 phase of embodiment in addition to each component content is different
Together.
A kind of probiotic composition of comparative example 4
The difference from example 2 is that: Lactobacillus rhamnosus HN001 freeze-dried powder and lactobacillus fermenti CECT5716 freeze-dried powder
The ratio between parts by weight be 1:5.
Preparation method: specific steps include: other operations and step and 2 phase of embodiment in addition to each component content is different
Together.
A kind of probiotic composition of comparative example 5
Difference with embodiment 3 is: bifidobacterium lactis HN019 freeze-dried powder, animal bifidobacteria BB-12 freeze-dried powder and short
The ratio between parts by weight of Bifidobacterium M-16V freeze-dried powder are 0.1:1:1.
Preparation method: specific steps include: other operations and step and 3 phase of embodiment in addition to each component content is different
Together.
A kind of probiotic composition of comparative example 6
Difference with embodiment 3 is: bifidobacterium lactis HN019 freeze-dried powder, animal bifidobacteria BB-12 freeze-dried powder and short
The ratio between parts by weight of Bifidobacterium M-16V freeze-dried powder are 5:1:1.
Preparation method: specific steps include: other operations and step and 3 phase of embodiment in addition to each component content is different
Together.
Experimental section
1, dissolubility test:
The probiotic composition solid beverage of embodiment 1-5 is added in about 40 DEG C of water and is gently mixed, about in 1-
It is completely dissolved in 2min.
2, security test:
10 volunteers are found, respectively the probiotic composition solid beverage 10- of daily early oral meal embodiment 1-5
20g does not have found the side effects such as diarrhea.
3, clinical detection
The present invention detects the Bifidobacterium in infant faeces, lactobacillus, short chain fatty acids, the content of sIgA.
The content of Bifidobacterium and lactobacillus in infant faeces can directly react Bifidobacterium and newborn bar in baby intestinal
Bacterium number amount number, the content of Bifidobacterium and lactobacillus in excrement is high, then Bifidobacterium and lactobacillus quantity are more in enteron aisle,
It is one of the index for measuring health status.
Beneficial bacterium in body enteron aisle can decompose the polysaccharide in food, be broken down into the short chain fatty acids such as acetic acid, propionic acid,
Therefore the content of the acetic acid, propionic acid in excrement can directly react the quantity of probiotics in enteron aisle, the content of short chain fatty acids is high, then
The quantity of probiotics is more in enteron aisle.
SIgA is the main effects factor of mucosal immune system, is primarily present in tear, saliva, milk and respiratory tract, disappears
Change in the mucous membrane surfaces juice such as road and urogenital tract.SIgA is in the invasion for mediating mucosa-immune to resist extraneous pathogenic microorganism
In play a significant role, have immunization.Therefore, the content of sIgA can react the immunity level of body, sIgA in excrement
Content is high, then the immunity of body is high
Experimental design: infant 200 for recruiting 6-12 monthly age health, control group are as follows: Pure breast feeding baby
50, ordinary powdered milk feeding infant 50, experimental group are as follows: infant is provided prebiotic using addition 8g embodiment of the present invention 1-5
The ordinary powdered milk of bacteria composition is fed.Test group and control set product take mode: it is oral, 27g/ times, 5 times/day.Product intervention
10 weeks.
Excrement laboratory testing: by specifying medical matters in after test baseline day, the 21st day and test intervention period
Personnel take whole volunteer's fecal samples, and every volunteer's feces collection is primary, and limit 1 gram, are put into and closed with cover detest
In oxygen sampling bottle, laboratory is sent under refrigerated condition immediately.To the fecal sample of baseline day and the 21st day carry out count of bacteria and
Short chain fatty acids detection, wherein fecal bacteria counts the detection including Bifidobacterium, living preparation of lactobacillus number, and detection method is using real
When quantitative PCR；The detection of short chain fatty acids includes acetic acid, propionic acid and butyric acid, and detection method uses gas chromatography.It is additionally right
Fecal sample after baseline day and test intervention period carries out the detection of sIgA, and detection method uses enzyme-linked immunoassay method.
Clinical monitoring result is as follows:
(1) Bifidobacterium in infant faeces and lactobacillus content detection result
Bifidobacterium and lactobacillus content in product patients before and after intervention each group infant faeces are shown in Table 1
Bifidobacterium and lactobacillus content (log10cfu/g) in 1 product patients before and after intervention each group infant faeces of table
By data in table 1 it is known that product intervenes Bifidobacterium and lactobacillus in preceding breast milk control group infant faeces
Content is significantly higher than ordinary powdered milk control group and adds the ordinary powdered milk test group (p of 1-5 of embodiment of the present invention probiotic composition
< 0.01), after 3 weeks products are intervened, the ordinary powdered milk test group baby of 1-5 of embodiment of the present invention probiotic composition is added
Bifidobacterium and lactobacillus content in youngster's excrement dramatically increase, and in breast milk control group and ordinary powdered milk control group infant faeces
Various micro-flora contents in patients before and after intervention without significant changes (p > 0.05).
It carries out otherness comparative analysis to the micro-flora content in each group infant faeces after product intervention to obtain, the addition present invention
Bifidobacterium and lactobacillus content in the ordinary powdered milk test group infant faeces of embodiment 1-5 probiotic composition are significantly higher than
Ordinary powdered milk control group (p<0.01), and there is no significant difference (p>0.05) with breast milk control group.This shows this test institute
The ordinary powdered milk of 1-5 probiotic composition of the embodiment of the present invention can significantly improve in baby intestinal compared with ordinary powdered milk
Bifidobacterium and lactobacillus content, to be effectively improved the micro-ecological environment of baby intestinal, i.e. the probiotic composition can be with
Make to interact between each bacterial strain by adjusting the type and content of probiotics, can preferably promote infant's stomach and intestine
Absorption to nutriment.
(2) the short chain fatty acids content detection result in infant faeces
Short-chain fat acid content in product patients before and after intervention each group infant faeces is shown in Table 2
Short-chain fat acid content (mg/g) in 2 product patients before and after intervention each group infant faeces of table
By data in table 2 it is known that the acetic acid content before product intervention in breast milk control group infant faeces is significantly higher than
The ordinary powdered milk test group of ordinary powdered milk control group and addition 1-5 of embodiment of the present invention probiotic composition, data have statistics
It learns meaning (p < 0.01).After 3 weeks products are intervened, the ordinary powdered milk of 1-5 of embodiment of the present invention probiotic composition is added
Various short-chain fat acid contents in test group infant faeces dramatically increase (p < 0.05), and breast milk control group and ordinary powdered milk
Control group is in patients before and after intervention without significant changes (p > 0.05).
Otherness comparative analysis is carried out to the short-chain fat acid content in each group infant faeces after product intervention to obtain, is added
Acetic acid content and propionic acid content in the ordinary powdered milk test group infant faeces of 1-5 probiotic composition of the embodiment of the present invention is aobvious
It writes and is higher than ordinary powdered milk control group (p < 0.05), this shows this test addition 1-5 probiotic combinations of the embodiment of the present invention used
The ordinary powdered milk of object can significantly improve the acetic acid content and propionic acid content in infant faeces compared with ordinary powdered milk, and close to pure
Breast feeding babies, the i.e. probiotic composition can promote the increase of enteron aisle Short-Chain Fatty Acids, improve the content of organic acid,
Gut pH is reduced, enteron aisle acidity is caused to reduce and inhibit harmful bacteria, is increased beneficial to bacterial content.
(3) the sIgA content detection result in infant faeces
SIgA content in product patients before and after intervention each group infant faeces is shown in Table 3
SIgA content (ng/g) in 3 product patients before and after intervention each group infant faeces of table
It carries out otherness comparative analysis to the sIgA content in each group infant faeces after product intervention to obtain, the addition present invention
SIgA content in the ordinary powdered milk test group infant faeces of embodiment 1-5 probiotic composition is significantly higher than ordinary powdered milk control
Group (p<0.01), and there is no significant difference (p>0.05) with breast milk control group.This shows this hair of addition used in this test
Compared with ordinary powdered milk, the sIgA that can be significantly improved in infant faeces contains the ordinary powdered milk of bright embodiment 1-5 probiotic composition
Amount, and close to Pure breast feeding baby.I.e. the probiotic composition can improve infant's intestinal flora diversity, can play
The effects of promoting digestion, stimulating intestine immunity cell, enhance infant's intestinal immunity.
It, will be of the invention in order to which the probiotic composition for further proving that the present invention discloses content and proportion has the effect of
Embodiment 1 is compared with comparative example 1-2, detects the Bifidobacterium in patients before and after intervention each group infant faeces and lactobacillus content
(log10cfu/g) 4 be see the table below.
Table 4
By data in table 4 it is known that product adds ordinary powdered milk baby's excrement of 1 probiotic composition of embodiment before intervening
Just 2 benefit of ordinary powdered milk and addition comparative example of Bifidobacterium and lactobacillus content and addition 1 probiotic composition of comparative example in
The ordinary powdered milk of raw bacteria composition does not have significant difference, after 3 weeks products are intervened, adds 1 probiotic composition of comparative example
Ordinary powdered milk and addition 2 probiotic composition of comparative example ordinary powdered milk infant faeces in Bifidobacterium and lactobacillus content
Though there is increase, change unobvious (p > 0.05), i.e., when probiotics additive amount is not in the open scope of the present invention, obtained benefit
Raw bacteria composition is little to the effect for increasing Bifidobacterium and lactobacillus in infants.
The embodiment of the present invention 2 and comparative example 3-6 are compared, the short-chain fat acid content (mg/ in infant faeces is detected
G).
Table 5
Otherness comparative analysis is carried out to the short-chain fat acid content in each group infant faeces after product intervention to obtain, is added
Acetic acid content and propionic acid content in the ordinary powdered milk test group infant faeces of 2 probiotic composition of the embodiment of the present invention is significant
Higher than ordinary powdered milk control group (p < 0.05), and add the ordinary powdered milk test group of comparative example 3-6 probiotic composition of the present invention
Though infant faeces in short-chain fat acid content increased variation be not obvious, this shows that probiotics additive amount does not exist
When in the open scope of the present invention, obtained probiotic composition is acted on not short chain fatty acids changes of contents in infants is increased
Greatly.
The above description is only an embodiment of the present invention, is not intended to limit the scope of the invention, all to utilize this hair
Equivalent structure or equivalent flow shift made by bright description is applied directly or indirectly in other relevant technology necks
Domain is included within the scope of the present invention.
Claims (4)
1. a kind of multifarious probiotic composition of improvement infant's intestinal flora, it is characterised in that: include according to parts by weight
Following components: 40-60 parts of resistant dextrin, 5-15 parts of galactooligosaccharide, 5-15 parts of oligofructose, bifidobacterium lactis HN019 freeze-drying
2-8 parts of powder, 2-8 parts of animal bifidobacteria BB-12 freeze-dried powder, 2-8 parts of bifidobacterium breve M-16V freeze-dried powder, Lactobacillus rhamnosus
2-8 parts and 2-8 parts of lactobacillus fermenti CECT5716 freeze-dried powder of HN001 freeze-dried powder；
Bifidobacterium lactis HN019 freeze-dried powder, animal bifidobacteria BB-12 freeze-dried powder and the bifidobacterium breve M-16V freeze-drying
The total weight number of powder is calculated as M1, the Lactobacillus rhamnosus HN001 freeze-dried powder and lactobacillus fermenti CECT5716 freeze-dried powder
Total weight number be calculated as M2, the ratio between M1 and M2 are 2-5: 2；
Bifidobacterium lactis HN019 freeze-dried powder, animal bifidobacteria BB-12 freeze-dried powder and the bifidobacterium breve M-16V freeze-drying
The ratio between parts by weight of powder are 0.5-3: 1: 1；
The ratio between described parts by weight of Lactobacillus rhamnosus HN001 freeze-dried powder and lactobacillus fermenti CECT5716 freeze-dried powder are 1:
0.5-4。
2. probiotic composition according to claim 1, it is characterised in that: according to parts by weight include following components: anti-
Property 50-60 parts of dextrin, 8-12 parts of galactooligosaccharide, 8-12 parts of oligofructose, 3-7 parts of bifidobacterium lactis HN019 freeze-dried powder, animal
3-7 parts of Bifidobacterium BB-12 freeze-dried powder, 3~7 parts of bifidobacterium breve M-16V freeze-dried powder, Lactobacillus rhamnosus HN001 freeze-dried powder
3-7 parts and 3-7 parts of lactobacillus fermenti CECT5716 freeze-dried powder.
3. probiotic composition according to claim 1, it is characterised in that: the bifidobacterium lactis HN019 freeze-dried powder,
Animal bifidobacteria BB-12 freeze-dried powder, bifidobacterium breve M-16V freeze-dried powder, Lactobacillus rhamnosus HN001 freeze-dried powder and acidified milk
The viable count of bacillus CECT5716 freeze-dried powder is 107-1010CFU/g, and moisture content is lower than 4%.
4. probiotic composition according to claim 1-3, it is characterised in that: the probiotic composition can
In terms of food additives, human food, veterinary drug and animal feed.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810719798.3A CN108753677B (en) | 2018-07-03 | 2018-07-03 | A kind of multifarious high-activity probiotics composition of improvement infant's intestinal flora |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810719798.3A CN108753677B (en) | 2018-07-03 | 2018-07-03 | A kind of multifarious high-activity probiotics composition of improvement infant's intestinal flora |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108753677A CN108753677A (en) | 2018-11-06 |
| CN108753677B true CN108753677B (en) | 2019-04-09 |
Family
ID=63976026
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810719798.3A Active CN108753677B (en) | 2018-07-03 | 2018-07-03 | A kind of multifarious high-activity probiotics composition of improvement infant's intestinal flora |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108753677B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022137148A1 (en) * | 2020-12-22 | 2022-06-30 | Fonterra Co-Operative Group Limited | Use of lactic acid bacteria to inhibit methanogen growth or reduce methane emissions |
| WO2022137149A1 (en) * | 2020-12-22 | 2022-06-30 | Fonterra Co-Operative Group Limited | Use of lactic acid bacteria to inhibit methanogen growth or reduce methane emissions |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109876092A (en) * | 2019-01-24 | 2019-06-14 | 金活医药集团有限公司 | Traditional Chinese medicine prebiotic composition, culture medium containing traditional Chinese medicine prebiotics, product combining traditional Chinese medicine prebiotics and probiotics, and preparation method thereof |
| CN110720638A (en) * | 2019-09-22 | 2020-01-24 | 深圳市多微生保健食品有限公司 | A kind of probiotics powder and its production method |
| EP3725167A1 (en) * | 2019-11-11 | 2020-10-21 | COREE S.r.l. | Synergistic blends of probiotics expressing improved beneficial activity for human host favourably interacting with food, particularly baby food |
| CN111264739A (en) * | 2020-03-31 | 2020-06-12 | 广州纽缤乐营养科技股份有限公司 | Probiotic solid beverage and preparation method thereof |
| CN114097937A (en) * | 2020-08-26 | 2022-03-01 | 河北科星药业有限公司 | Feed additive for preventing diarrhea and improving immunity and preparation method and application thereof |
| CN113679048A (en) * | 2021-08-06 | 2021-11-23 | 吉林省红五味生物技术有限公司 | High-activity probiotic freeze-dried powder for adjusting balance of intestinal flora of infants |
| CN113812632A (en) * | 2021-09-16 | 2021-12-21 | 江南大学 | Micromolecular sugar/hyaluronic acid/calcium ion cross-linked polysaccharide gel beads and preparation method thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103053904A (en) * | 2012-12-29 | 2013-04-24 | 北京中科邦尼国际科技有限责任公司 | Compound functional sugar with function of adjusting intestinal flora |
| CN106434438A (en) * | 2016-09-20 | 2017-02-22 | 杭州益儒信息科技有限公司 | Preparation method and application of high-stress-resistant probiotics |
| CN106244511A (en) * | 2016-09-20 | 2016-12-21 | 杭州益儒信息科技有限公司 | The high-density cultivation method of a kind of probiotic bacteria and application thereof |
-
2018
- 2018-07-03 CN CN201810719798.3A patent/CN108753677B/en active Active
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022137148A1 (en) * | 2020-12-22 | 2022-06-30 | Fonterra Co-Operative Group Limited | Use of lactic acid bacteria to inhibit methanogen growth or reduce methane emissions |
| WO2022137149A1 (en) * | 2020-12-22 | 2022-06-30 | Fonterra Co-Operative Group Limited | Use of lactic acid bacteria to inhibit methanogen growth or reduce methane emissions |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108753677A (en) | 2018-11-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108753677B (en) | A kind of multifarious high-activity probiotics composition of improvement infant's intestinal flora | |
| CN104544086B (en) | A health food capable of improving intestinal flora and preparation method thereof | |
| CN104509864B (en) | A kind of have nutritional health food improving gastrointestinal function and preparation method thereof | |
| CN104489646B (en) | A kind of fruit and vegerable probiotic tablet and preparation method thereof | |
| CN108823129B (en) | A kind of high-activity probiotics solid beverage with disinfecting helicobacter pylori effect | |
| CN105146614B (en) | A kind of functional calcium fruit ferment, enzyme beverage and its production method | |
| CN106244511A (en) | The high-density cultivation method of a kind of probiotic bacteria and application thereof | |
| CN108991327A (en) | A kind of probiotics solid beverage and preparation method thereof | |
| CN104432092A (en) | Probiotic tablet and preparation method thereof | |
| CN109619593A (en) | A kind of probiotic double layer microcapsules and preparation method thereof | |
| CN104473183A (en) | Weight-losing probiotic tablets and preparation method thereof | |
| CN105167072A (en) | Production method of functional Chinese wolfberry fruit enzyme and product thereof | |
| CN104543679A (en) | Probiotic-containing health food and preparation method thereof | |
| CN102318806B (en) | Preparation method of probiotics fermented pumpkin and carrot vegetable powder | |
| CN104770816A (en) | Watermelon juice probiotic fermented beverage and preparation method thereof | |
| CN110353144A (en) | A kind of probiotics solid beverage and its preparation process | |
| CN105123931A (en) | Probiotic foodstuff and preparation method thereof | |
| CN105779343A (en) | Lactobacillus plantarum capable of effectively removing cholesterol and free radicals and application thereof | |
| CN104543680A (en) | Health food for resisting fatigue and improving gastrointestinal functions and preparation method of health food | |
| CN102204679A (en) | Quadruple bacterial tablets and preparation method thereof | |
| CN106434438A (en) | Preparation method and application of high-stress-resistant probiotics | |
| CN106497821A (en) | A kind of food materials are used for the method for probiotic's culture and its application | |
| CN105076440A (en) | Freeze-dried fruit and vegetable yoghurt tablet and preparation method thereof | |
| CN104982526A (en) | Yoghourt slice and preparation method thereof | |
| CN105230782A (en) | Preparation method of hair weed yoghourt |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |